Commissioner of Human Services establishment of a directed pharmacy dispensing payment to improve and maintain access to pharmaceutical services; appropriating money
SF2152 requires the Commissioner of Human Services to create a directed pharmacy dispensing payment of $4.50 per filled prescription for eligible outpatient retail pharmacies in Minnesota. The payment would apply to drugs dispensed to Medical Assistance enrollees through managed care and county-based purchasing plans, and through pharmacy benefit managers under contract with those entities. The stated purpose is to improve and maintain access to pharmaceutical services, especially in rural and underserved areas of the state.
The bill defines which pharmacies qualify for the payment. Eligible pharmacies must be licensed outpatient retail pharmacies that are not owned, directly or indirectly, by a pharmacy benefit manager or health carrier, and must either be located in a medically underserved area or primarily serve a medically underserved population, or share common ownership with 12 or fewer Minnesota pharmacies. Pharmacies would need to submit an attestation form to the commissioner to receive the payment. The commissioner is also directed to set and adjust the payment amount based on available state and federal funding and to monitor the effect on access to pharmacy services.
The bill also addresses federal approval and Medicaid financing rules. If federal approval is not received for a contract year, the commissioner must adjust managed care capitation rates to remove the cost of the payment, and contracts must allow recovery of overpayments consistent with those adjustments. If federal approval is never obtained, the subdivision expires. The bill takes effect July 1, 2025, or upon federal approval, whichever is later, and includes an unspecified general fund appropriation for fiscal years 2026 and 2027 to support the payments.
Because there are no committee transcripts or recorded votes in the provided materials, the overall sentiment cannot be measured from debate or roll call history. Based on the bill text and caption, the measure appears intended to support independent and small pharmacies and improve access in underserved communities, suggesting a generally pro-access, pro-pharmacy policy goal. No explicit opposition is documented in the supplied record, but the structure of the bill indicates likely sensitivity around payment costs, managed care rate adjustments, and the exclusion of pharmacies owned by PBMs or health carriers.
The main points of contention likely concern whether the directed payment is necessary or cost-effective, how it will affect managed care plans and pharmacy benefit managers, and whether the ownership-based eligibility rules are fair or sufficiently targeted. Another possible issue is the need for federal approval and the bill’s dependence on Medicaid financing rules, which could affect implementation timing and the final payment amount.
The bill would amend Minnesota Statutes section 256B.69 by adding a new subdivision requiring directed pharmacy dispensing payments for certain outpatient retail pharmacies serving Medical Assistance enrollees. It would create a new state-administered payment mechanism within the managed care and county-based purchasing framework, require participating plans and their pharmacy benefit managers to make the payments, and authorize the commissioner to adjust the payment amount based on available funding. It also creates a new general fund appropriation for the program and establishes contingency rules if federal approval is not obtained.
No committee discussion or votes were provided, so there is no recorded legislative sentiment to summarize from debate or roll call history. From the bill’s language and caption, the measure appears to have a supportive policy intent focused on preserving pharmacy access in rural and underserved areas and assisting eligible retail pharmacies. The absence of recorded opposition or amendments in the supplied materials means sentiment cannot be characterized beyond that general pro-access framing.
The likely areas of contention are the cost of the directed payment, its effect on managed care capitation rates, and whether the state should require plans and pharmacy benefit managers to fund an additional per-prescription payment. Another possible dispute is the eligibility definition, which excludes pharmacies owned by PBMs or health carriers and favors pharmacies in underserved areas or with limited common ownership, potentially drawing concerns about market fairness, administrative complexity, or whether the criteria are too narrow or too broad. Federal approval requirements and the possibility of payment recovery if rates are adjusted may also be contentious because they add implementation uncertainty and financial risk.